Citation Impact
Citing Papers
The discovery and development of HMG-CoA reductase inhibitors.
1992
Finding multiple target optimal intervention in disease‐related molecular network
2008
Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
2001
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
2007
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
2005
Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
2002
Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
1990 Standout
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents
1998
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
2003 Standout
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
2004
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis
2006
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism
1991 Nature
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
2000 Standout
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
Juvenile idiopathic arthritis
2007 Standout
Albumin–drug interaction and its clinical implication
2013 Standout
Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part II)
1994
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Network medicine: a network-based approach to human disease
2010 Standout
Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians
2017 Standout
Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly
2003
Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
1999
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
2003
Differential Inhibition of HMG-CoA Synthase and Pancreatic Lipase by the Specific Chiral Isomers of β-Lactone DU-6622
1999 StandoutNobel
Asthma
2017 Standout
Inflammation and Colon Cancer
2010 Standout
Impact of a Soluble Phospholipase A2Inhibitor on Inhaled Allergen Challenge in Subjects with Asthma
2005
Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis
2002
Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol
1990
Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase.
1992
Coxibs and Cardiovascular Disease
2004 Standout
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
2008
Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment.
1989
Systemic amyloidosis
2015 Standout
Regulation of the mevalonate pathway
1990 StandoutNature
Clinician’s Guide to Cardiopulmonary Exercise Testing in Adults
2010 Standout
A crevice adjoining the ribosome tunnel: Hints for cotranslational folding
2005 StandoutNobel
The blood-brain barrier and oncology: new insights into function and modulation
2000
Eicosanoids and cancer
2010 Standout
Indirect airway challenges
2003
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone)
2002
Knowledge-based design of bimodular and trimodular polyketide synthases based on domain and module swaps: a route to simple statin analogues
1999
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
2004
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Renal Effects of COX-2-Selective Inhibitors
2001
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
2001
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain
2003
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
2003
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
2003
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
2004
International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding
2010 Standout
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Christian Raetz: Scientist and Friend Extraordinaire
2013 StandoutNobel
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
2006
Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis.
1992 StandoutNobel
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
1984
Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease
2011
Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
1989
Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis
2016 Standout
Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers.
1984
Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of Amyloidogenesis
2003
Total Synthesis of α-Pyrone Meroterpenoids, Novel Bioactive Microbial Metabolites
2005 StandoutNobel
A Receptor-Mediated Pathway for Cholesterol Homeostasis
1986 StandoutScienceNobel
Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signaling
2017 Standout
Inhibition of hydroxymethylglutaryl-coenzyme A synthase by L-659,699.
1987
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by β-lactone inhibitors and binding of these inhibitors to the enzyme
1993
Dioxygen Activation at Mononuclear Nonheme Iron Active Sites: Enzymes, Models, and Intermediates
2004 Standout
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
2011 Standout
Pharmacological and immunohistochemical evidence for a functional nitric oxide synthase system in rat peritoneal eosinophils
1997 StandoutNobel
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.
1986
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
1983
Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme
1985 StandoutNobel
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
2004 Standout
Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2
2008 StandoutNobel
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Reduction of Serum Cholesterol in Heterozygous Patients with Familial Hypercholesterolemia
1983
Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology
1984
Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia
1984
Synthesis of Four Chiral Isomers of β-Lactone DU-6622 and Inhibition of HMG-CoA Synthase by the Specific (2R,3R)-Isomer
1997 StandoutNobel
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
2004 StandoutScience
Applied Hydroformylation
2012 Standout
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Liver Transplantation to Provide Low-Density-Lipoprotein Receptors and Lower Plasma Cholesterol in a Child with Homozygous Familial Hypercholesterolemia
1984 StandoutNobel
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
2001
The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
2002
Works of A. Buntinx being referenced
Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans
1993
Oral Leukotriene Inhibitor (MK-886) Blocks Allergen-induced Airway Responses
1993
MK-571, a Potent Antagonist of Leukotriene D 4 -induced Bronchoconstriction in the Human
1991
Hormonal effects of an orally active 4‐azasteroid inhibitor of 5α‐reductase in humans
1989
Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man
1992
Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic
1980
Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio
1981
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers
2000
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
1982